Evarrest market projected to grow on rising surgery volumes and bleeding-control demand

The Business Research Company says the Evarrest market is set for growth through 2035 as surgery volumes rise, hospitals expand, and surgeons look for faster bleeding control. North America led in 2025, while Asia-Pacific is expected to grow the fastest.

Why it matters: - Evarrest is a bleeding-control product used in surgery, so market growth tracks demand for safer, faster procedures and better outcomes. - Rising surgical volumes, trauma cases and hospital expansion point to broader adoption of ready-to-use hemostatic patches. - The forecast matters for hospitals, surgeons and medical-device buyers looking for tools that reduce operating-room delays and complications.

What happened: - The Business Research Company published the Evarrest Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Evarrest market is gaining attention as surgical techniques and patient care continue to evolve. - The report highlights expected growth through 2035 across global markets. - Download a free sample of the report. - View the full market report.

The details: - Evarrest is an FDA-approved fibrin sealant patch designed to manage bleeding during surgery. - The patch is coated with human fibrinogen and thrombin to support quick clot formation. - Evarrest requires no preparation before use. - The product can stop bleeding on the first attempt, which can streamline surgical workflows. - Historical market growth was supported by high rates of surgical bleeding complications and the limits of traditional suturing techniques. - Early uptake of fibrin sealants, more surgeries and demand for faster bleeding control also helped expansion. - Future growth is expected to be driven by more complex surgical procedures, higher trauma volumes, expanding hospital infrastructure and stronger surgeon preference for sealant patches. - Advances in surgical biomaterials are also supporting the market outlook. - Key trends include demand for rapid surgical hemostasis, wider use of ready-to-use hemostatic patches, more emergency and trauma surgeries, preference for solutions requiring no preparation and expansion of advanced surgical care facilities. - The increasing volume of surgical procedures worldwide is a major growth driver. - Surgical interventions have become more common because of an aging population and advances in medical technology. - Evarrest is placed directly on bleeding sites to facilitate rapid clot formation. - The UK Health Security Agency reported 27,524 coronary artery bypass graft surgeries in the UK in 2023. - The rising adoption of personalized medicine is another growth driver. - Personalized medicine tailors treatment to a person’s genetic profile, lifestyle and specific health needs. - The Personalized Medicine Coalition said the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022. - Rising healthcare expenditure is also supporting market growth. - The U.S. Centers for Medicare & Medicaid Services reported U.S. healthcare spending rose 7.5% in 2023 to $4.9 trillion, after a 4.6% increase in 2022.

Between the lines: - The report suggests hospitals are favoring products that reduce preparation time and improve intraoperative efficiency. - Growth in personalized medicine and healthcare spending signals that advanced surgical tools are benefiting from broader shifts in care delivery and reimbursement capacity. - The market case for Evarrest is tied less to one procedure type and more to a wider push for faster, simpler bleeding control across complex surgeries.

What's next: - North America held the largest share of the Evarrest market in 2025, supported by advanced healthcare infrastructure and high surgical volumes. - Asia-Pacific is expected to grow the fastest during the forecast period because of expanding hospital facilities and more surgical procedures. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report package adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - The Business Research Company provided contact details for expert inquiries, including Saumya Sahay and marketing@tbrc.info.

The bottom line: - Evarrest’s market outlook is being driven by more surgery, more demand for rapid hemostasis and more adoption of ready-to-use surgical products.